← Oncology Approval Tracker

FDA DECISION ·

Revuforj

revumenib · Syndax Pharmaceuticals

FDA approvalNew or expanded indicationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 1 year or older with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternative treatment options.

LAMPGEN ANALYSIS

Why it matters

This approval extends menin inhibition from KMT2A-rearranged acute leukemia to susceptible NPM1-mutated AML.

What research teams should watch

Set up rapid molecular testing at relapse and align early differentiation syndrome and ECG monitoring across sites.

PRIMARY RECORDS

Sources